Key result
ACEI or ARB prescription was associated with severe COVID-19 outcomes, but this was lost in sensitivity analyses and likely due to confounding baseline risk factors rather than the drugs.
Why the study?
Conflicting findings and the analysis of unpublished and retracted data led to controversy regarding the safety of ACE inhibitors and ARBs in patients with COVID-19 infection.
Does prescription of ACEI or ARB increase severe disease or mortality in patients with COVID-19?
Meta-Analysis (n=29,378)
Yes
Does prescription of ACEI or ARB increase severe disease or mortality in patients with COVID-19?
Prescription of ACEI or ARB is not independently associated with increased mortality or severe disease in COVID-19 patients, with apparent risks likely driven by underlying comorbidities.
Answers are grounded in this paper and cite their sources.
Reassures on ACEI/ARB continuation in COVID-19; strengthens meta-analytic evidence of no independent mortality risk.
Background Conflicting findings and the analysis of unpublished and retracted data have led to controversy on the safety of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in people with COVID-19 infection. This meta-analysis examined the association of prescription of angiotensin-converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) with the outcome from COVID-19. Methods A systematic search was conducted to find published studies that reported the outcome of COVID-19 in relation to prescription of ACEI or ARB. Two authors (MF and AD) independently screened and extracted data and assessed study quality and strength of association using standardised tools. The endpoints for the meta-analyses were severe or critical disease outcome and mortality based on standardised criteria. Results Twenty-six studies including 8389 people prescribed ACEI or ARB and 20,989 people not prescribed these medications were included. The quality of studies varied, and the overall strength of association was poor with a high risk of confounding bias. Patients prescribed ACEI or ARB had a greater prevalence of risk factors. Meta-analysis found an association between prescription of ACEI or ARB with severe or critical disease outcome (risk ratio, RR, 1.23, 95% confidence interval, CI, 1.06 to 1.42, p = 0.006, I 2 = 88%) but this association was lost in sensitivity analyses. There was no association between ACEI or ARB prescription and mortality (RR 1.18, 95% CI 0.92 to 1.50, p = 0.19, I 2 = 82%). Conclusions This meta-analysis suggests that people prescribed ACEI or ARB more commonly had severe or critical disease outcome, but not mortality, in published cohorts of patients diagnosed with COVID-19. This finding is most likely due to a greater prevalence of risk factors in these patients rather than due to exposure to angiotensin pathway inhibitors.
No takes yet. Share an insight, caveat, or question.
Fernando et al. (2021) conducted a meta-analysis in COVID-19 (n=29,378). Angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) vs. No ACEI or ARB prescription was evaluated on Severe or critical disease outcome (RR 1.23, 95% CI 1.06 to 1.42, p=0.006). ACEI or ARB prescription was associated with severe COVID-19 outcomes, but this was lost in sensitivity analyses and likely due to confounding baseline risk factors rather than the drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: